Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium

Cancer Letters

Volumn 248, Issue 1, 2007, Pages 112-122

  Minaguchi, Takeo ^a   Nakagawa, Shunsuke ^a   Takazawa, Yutaka ^b   Nei, Tomomi ^a   Horie, Koji ^a   Fujiwara, Toshihiro ^a   Osuga, Yutaka ^a   Yasugi, Toshiharu ^a   Kugu, Koji ^a   Yano, Tetsu ^a   Yoshikawa, Hiroyuki ^c   Taketani, Yuji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Akt; Atypical hyperplasia; Endometrial Carcinoma; MPA; PTEN

Indexed keywords

CISPLATIN; CLOMIFENE CITRATE; CYCLOFENIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN RECEPTOR; PROTEIN KINASE B; PROTEIN P53;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RELAPSE; CLINICAL ARTICLE; COMPLEX ATYPICAL HYPERPLASIA; CORRELATION ANALYSIS; DRUG RESPONSE; DRUG TREATMENT FAILURE; ENDOMETRIUM CARCINOMA; EVALUATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; INFERTILITY THERAPY; PREDICTION; PREGNANCY; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; COMBINED MODALITY THERAPY; CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PREGNANCY; PROGESTINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33847298630     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.06.013     Document Type: Article

References (32)

1. Ramirez P.T., Frumovitz M., Bodurka D.C., Sun C.C., and Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol. Oncol. 95 (2004) 133-138
2. Zheng W., Baker H.E., and Mutter G.L. Involution of PTEN-null endometrial glands with progestin therapy. Gynecol. Oncol. 92 (2004) 1008-1013
3. Kaku T., Yoshikawa H., Tsuda H., Sakamoto A., Fukunaga M., Kuwabara Y., Hataeg M., Kodama S., Kuzuya K., Sato S., Nishimura T., Hiura M., et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett. 167 (2001) 39-48
4. Lurain J.R. Uterine cancer. In: Berek J.S., Adashi E.Y., and Hillard P.A. (Eds). Novak's Gynecology. 12th ed. (1996), Williams & Wilkins, Baltimore 1057-1110
5. Risinger J.I., Hayes A.K., Berchuck A., and Barrett J.C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57 (1997) 4736-4738
6. Kong D., Suzuki A., Zou T.T., Sakurada A., Kemp L.W., Wakatsuki S., Yokoyama T., Yamakawa H., Furukawa T., Sato M., Ohuchi N., Sato S., et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat. Genet. 17 (1997) 143-144
7. Risinger J.I., Hayes K., Maxwell G.L., Carney M.E., Dodge R.K., Barrett J.C., and Berchuck A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin. Cancer Res. 4 (1998) 3005-3010
8. Minaguchi T., Yoshikawa H., Oda K., Ishino T., Yasugi T., Onda T., Nakagawa S., Matsumoto K., Kawana K., and Taketani Y. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin. Cancer Res. 7 (2001) 2636-2642
9. Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C., Berchuck A., and Futreal P.A. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 58 (1998) 2500-2503
10. Levine R.L., Cargile C.B., Blazes M.S., van Rees B., Kurman R.J., and Ellenson L.H. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. 58 (1998) 3254-3258
11. Di Cristofano A., and Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 100 (2000) 387-390
12. Waite K.A., and Eng C. Protean PTEN: form and function. Am. J. Hum. Genet. 70 (2002) 829-844
13. Marino M., Acconcia F., and Trentalance A. Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol. Biol. Cell 14 (2003) 2583-2591
14. Guzeloglu-Kayisli O., Kayisli U.A., Al-Rejjal R., Zheng W., Luleci G., and Arici A. Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium. J. Clin. Endocrinol. Metab. 88 (2003) 5017-5026
15. Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F., Hamilton T.C., Tsichlis P.N., and Testa J.R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA 89 (1992) 9267-9271
16. Cheng J.Q., Ruggeri B., Klein W.M., Sonoda G., Altomare D.A., Watson D.K., and Testa J.R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. USA 93 (1996) 3636-3641
17. Downward J. PI 3-kinase, Akt and cell survival. Semin. Cell Dev. Biol. 15 (2004) 177-182
18. Kanamori Y., Kigawa J., Itamochi H., Shimada M., Takahashi M., Kamazawa S., Sato S., Akeshima R., and Terakawa N. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin. Cancer Res. 7 (2001) 892-895
19. Stambolic V., MacPherson D., Sas D., Lin Y., Snow B., Jang Y., Benchimol S., and Mak T.W. Regulation of PTEN transcription by p53. Mol. Cell 8 (2001) 317-325
20. Mayo L.D., Dixon J.E., Durden D.L., Tonks N.K., and Donner D.B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J. Biol. Chem. 277 (2002) 5484-5489
21. Viglietto G., Motti M.L., Bruni P., Melillo R.M., D'Alessio A., Califano D., Vinci F., Chiappetta G., Tsichlis P., Bellacosa A., Fusco A., and Santoro M. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 8 (2002) 1136-1144
22. Liang J., Zubovitz J., Petrocelli T., Kotchetkov R., Connor M.K., Han K., Lee J.H., Ciarallo S., Catzavelos C., Beniston R., Franssen E., and Slingerland J.M. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8 (2002) 1153-1160
23. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., and Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 (2000) 538-541
24. Yoshino O., Osuga Y., Hirota Y., Koga K., Yano T., Tsutsumi O., and Taketani Y. Akt as a possible intracellular mediator for decidualization in human endometrial stromal cells. Mol. Hum. Reprod. 9 (2003) 265-269
25. Chen B., Pan H., Zhu L., Deng Y., and Pollard J.W. Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase → AKT → GSK-3β → cyclin D1 → pRb pathway to block uterine epithelial cell proliferation. Mol. Endocrinol. 19 (2005) 1978-1990
26. Parsons R., and cancer H. PTEN and the PI-3 kinase pathway. Semin. Cell Dev. Biol. 15 (2004) 171-176
27. Kwon J., Lee S.R., Yang K.S., Ahn Y., Kim Y.J., Stadtman E.R., and Rhee S.G. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc. Natl. Acad. Sci. USA 101 (2004) 16419-16424
28. Agrawal S., Pilarski R., and Eng C. Differential splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN. Hum. Mol. Genet. 14 (2005) 2459-2468
29. Cip1,Waf1 through activation of p53 in human breast and endometrial tumor cells. Exp. Cell Res. 284 (2003) 264-273
30. Brooks C.L., and Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15 (2003) 164-171
31. Yang L., Dan H.C., Sun M., Liu Q., Sun X.M., Feldman R.I., Hamilton A.D., Polokoff M., Nicosia S.V., Herlyn M., Sebti S.M., and Cheng J.Q. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 64 (2004) 4394-4399
32. Jin X., Gossett D.R., Wang S., Yang D., Cao Y., Chen J., Guo R., Reynolds R.K., and Lin J. Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br. J. Cancer 91 (2004) 1808-1812